Moderna completes FDA submission for use of COVID shot in adolescents, kids By Reuters

© Reuters. FILE PHOTO: A vial labelled "Moderna COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - Moderna (NASDAQ:MRNA) Inc has made all necessary submissions required by the U.S. Food & Drug Administration for emergency use authorization of its COVID-19 vaccine in adolescents and children, it said on Wednesday.

The company is seeking approval for the use of its vaccines in three distinct age groups - adolescents aged 12 to 17 years, children aged six to 11 and those between six years and six months. The submissions for all three groups were made on May 9, it said.

Although Moderna's vaccine is approved by the FDA for use in adults 18 years and older, its use in other age groups has hit a roadblock as U.S. regulators have sought more safety data.

Australia, Canada and the European Union though have approved the vaccine for use in six- to 17-year olds.

The company sought U.S. authorization of its COVID shot in children under the age of 6 in April.

An advisory panel of experts to the U.S. drug regulator will meet in June to review the request.

Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!